News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Mar 4, 2020

  Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease

  -- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --
• Feb 26, 2020

  Insmed to Present at the Cowen and Company 40th Annual Health Care Conference
• Feb 25, 2020

  Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

  --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year 2019--
• Feb 19, 2020

  Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference
• Feb 10, 2020

  Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download